Lipocine Inc.

For the period ended Dec 31, 2025. Filed Mar 10, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 10, 2026

LPCN$1.72+9.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$5,205,842	$6,205,926
Marketable investment securities	9,724,545	15,427,385
Accrued interest income	14,189	120,447
License fee and royalties receivable	1,145,390	91,405
Prepaid and other current assets	787,600	476,510
Total current assets	16,877,566	22,321,673
Property and equipment, net of accumulated depreciation of $1,284,079 and $1,223,297, respectively	104,293	165,075
Other assets	23,753	23,753
Total assets	$17,005,612	$22,510,501
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$971,822	$271,696
Accrued expenses	1,236,374	921,240
Deferred revenue	320,000	320,000
Total current liabilities	2,528,196	1,512,936
Total liabilities	2,528,196	1,512,936
Commitments and contingencies (notes 8 and 11)	-	-
Stockholders’ equity:
Common stock, par value $0.0001 per share, 75,000,000 shares authorized; 6,158,779 and 5,348,276 issued and 6,158,443 and 5,347,940 outstanding, respectively	8,944	8,863
Additional paid-in capital	223,901,106	220,789,138
Treasury stock at cost, 336 shares	(40,712)	(40,712)
Accumulated other comprehensive gain	4,445	9,138
Accumulated deficit	(209,396,367)	(199,768,862)
Total stockholders’ equity	14,477,416	20,997,565
Total liabilities and stockholders’ equity	$17,005,612	$22,510,501

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.